Athenex announces u.s. launch of klisyri® and licensing of additional territories for tirbanibulin

Buffalo, n.y., feb. 18, 2021 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that today marks the u.s. launch of klisyri® (tirbanibulin) in the united states, led by the company's partner almirall. athenex announced the licensing of additional territories for tirbanibulin to its partner pharmaessentia corp. (taiwan exchange: 6446). athenex received approval from the u.s. food and drug administration (fda) for klisyri® for the topical treatment of actinic keratosis of the face or scalp on december 14, 2020.
ATNX Ratings Summary
ATNX Quant Ranking